Illumina, Inc.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis. Its products include whole-genome sequencing kits, genotyping assays, noninvasive prenatal testing solutions, and targeted resequencing kits that sequence exomes, specific genes, or RNA. The company also offers instruments and consumables such as reagents, flow cells, and library preparation kits. Illumina serves a wide range of customers including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics firms. The company markets its products directly and through life-science distributors.

Illumina, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ILMN. Its shares are traded in US Dollars (USD). The company is headquartered in the United States and is part of the US region.

Illumina operates in the Healthcare sector and is classified under the Diagnostics & Research industry. This means the company focuses on providing diagnostic tools and research solutions, particularly in genetic and genomic analysis, which supports healthcare providers, researchers, and laboratories in understanding and treating diseases at the molecular level.

Illumina serves customers across multiple regions including the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company has a global presence, with its solutions used by genomic research centers, academic institutions, hospitals, and commercial laboratories worldwide. It also has strategic collaborations, such as with Labcorp Holdings Inc. for oncology treatment development and with Integrated DNA Technologies for an integrated somatic oncology research solution.

Illumina's portfolio includes sequencing- and array-based instruments and consumables like reagents, flow cells, and library preparation kits. Key products include whole-genome sequencing kits for sequencing entire genomes of various sizes and complexities, and targeted resequencing kits for exomes, specific genes, or RNA. The company also offers noninvasive prenatal testing solutions and product support services. Additionally, Illumina has a data partnership with the Center for Data-Driven Discovery in Biomedicine to advance pediatric cancer and rare disease research.